Moderna Says That the Cancer Vaccine and Keytruda Combination Trial Went Well

CHAM, Switzerland - April 10, 2024 - PRLog -- Moderna (MRNA) shares rose on Tuesday after the biotech company revealed promising findings from a small study involving patients with head and neck cancer who received its experimental customized MRNA cancer vaccine in combination with Merck's (MRK) blockbuster medicine Keytruda.

The trial included 22 patients with human papillomavirus negative (HPV-) head and neck squamous cell carcinoma who were given Moderna's mRNA-4157 injection with Keytruda.

The business said that the medicine combination resulted in "preliminary positive clinical responses and disease control," including two full responses. It went on to say that the medication was well tolerated while also enhancing the immunological response.

The findings were presented at the American Association for Cancer Research's annual conference in San Diego, California, yesterday. According to Moderna's analysis, a randomized study of the mRNA-4157-Keytruda combination's efficacy in advanced illness settings "may be warranted."

Moderna and Merck announced in December that they will start a Phase 3 study of the two medications to treat certain types of lung cancer.

Moderna stock rose 6.2% to finish at $111.60, giving it the S&P 500's largest gainer on Tuesday. Merck's stock finished 0.1% higher at $126.71.

Catch up-to-date press release and more at Medical Infralytix Pvt Ltd services, do visit our website at https://meditherma.com/ or contact us thru email.